Eduardo Garcia, MD
Pain Medicine · Webster, TXNPI 1578519757
Payments from drug & device makers
Across 574 payments — averaging $336.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nevro Corp.$95K
- Flowonix Medical Incorporated$30K
- Stratus Medical, LLC$24K
- Vertos Medical, Inc.$16K
- Boston Scientific$9K
- Tersera Therapeutics LLC$7K
- plus $11K from 42 others
Across 1 payment — averaging $4500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Nevro Corp.$5K
What the payments were for
- Consulting fees$98,86167%
- Speaking & faculty fees$18,67013%
- Travel & lodging$10,8877%
- Food & beverage$17,58812%
- Education$5000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnia$37,004
- Prometra II$30,034
- Nimbus$21,322
- mild Device Kit$15,918
- Senza$9,163
- PRIALT$5,981
- WAVEWRITER ALPHA$5,400
- Evoke$2,151
- Intracept$1,935
- Senza Spinal Cord Stimulation System$1,497
- SYNCHROMEDII$878
- GENERAL PAIN MANAGEMENT$448
- INTELLIS ADAPTIVESTIM$391
- Superion ISS$348
- V-LOC 180$235
- SUPERION$223
- Prospera$150
- BIOTRONIK$140
- INTELLIS$132
- Proclaim IPG$123
How this compares
$192,994 in reported general payments places this provider in the 95th percentile of 583 pain medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nucynta ErTapentadol Hcl | 15 | $35,631 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 751 | $16,930 |
| OxycontinOxycodone Hcl | 23 | $15,357 |
| NucyntaTapentadol Hcl | 15 | $14,986 |
| BelbucaBuprenorphine Hcl | 23 | $14,065 |
| MovantikNaloxegol Oxalate | 28 | $12,107 |
| SavellaMilnacipran Hcl | 15 | $10,057 |
| Buprenorphine | 31 | $7,430 |
| Fentanyl | 73 | $7,315 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 190 | $4,847 |
| Hydromorphone ErHydromorphone Hcl | 12 | $4,812 |
| Lidocaine | 18 | $4,374 |
| Morphine Sulfate ErMorphine Sulfate | 122 | $3,850 |
| Gabapentin | 195 | $2,618 |
| Hydromorphone Hcl | 115 | $2,150 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Nucynta Er, Nucynta, Belbuca | $206 | $64,68253 claims |
| Redhill Biopharma Inc.Movantik | $43 | $12,10728 claims |
| AbbVieSavella | $382 | $10,05715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 583 pain medicine providers in Texas.
Other pain medicine in Webster
- Mohamad AzzamWebster$51K
- Steven CannellaWebster$28K
- Aaron CalodneyTyler$3M
- Mitchell EngleHouston$1.5M
- Melissa MurphyGrapevine$711K
- Shiraz YazdaniLubbock$632K
- Muhammad ZulqarnainDallas$556K
- Daniel PakHouston$460K
- Marvin ChangSugar Land$306K
- David LeimanHouston$281K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.